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Abstract
Antibodies against HIV-1 proteins in HIV-1-infected indi-
viduals share a cross-reactive idiotype defined by the mono-
clonal antiidiotypic antibody 1F7 (5). Using a computer
algorithm based on the molecular recognition theory, re-
gions of inverse hydropathy between the variable sequence
of 1F7 and human monoclonal anti-HIV-1 antibodies were
identified, which are assumed to be involved in idiotype-
antiidiotype contacts. A peptide was designed from the pro-
posed contact in the variable heavy chain framework 3-
complementarity determining region 3 (FR3-CDR3) of hu-
man antibodies and was synthesized. This peptide is recog-
nized by the antiidiotype 1F7 and inhibits the binding of
1F7 to human anti-HIV-1 antibodies which express the 1F7
idiotype. A survey of normal and HIV-1-infected sera re-
vealed the presence of antibodies in infected sera which
bind to the FR3-CDR3 peptide. The biological relevance of
autoantibodies against a self idiotope associated with HIV-
1 infection is discussed in the context of the regulation of
the antibody response to HIV-1. (J. Clin. Invest. 1995.
96:775-780.) Key words: HIV-1 * AIDS * autoantibody
idiotype * peptide
Introduction
The function of idiotypic networks has been discovered in a
large number of experimental immune responses as well as in
diseases (for review see reference 1). In several of these im-
mune responses, idiotypes and antiidiotypes have been used to
manipulate or induce immunities (for review see reference 2).
A general obstacle in the idiotype network approach is the
imprecise knowledge of idiotypic structures on immunoglobu-
lins and T cell receptors. Recently, a new method has been used
to identify the molecular contacts between (CDRs)' of idiotype
Address correspondence to Heinz Kohler, 205 Combs Research Build-
ing, Markey Cancer Center, University of Kentucky Medical Center,
800 Rose Street, Lexington, KY 40536-0096. Phone: 606-257-6486;
FAX: 606-257-8940.
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1. Abbreviations used in this paper: CDR, complementarity determining
region; FR, framework; HRP, horseradish peroxidase; IDR, idiotope
determining region.
and antiidiotypes (3). This approach is based on hydropathic
complementarity, the so-called molecular recognition theory,
which predicts the sequence regions involved in protein-protein
interactions (4). This theory allows one to search protein se-
quences using a known ligand for regions which have inverse
hydropathies and thus the potential for binding to the ligand
probe. Whenapplied to antiidiotypic antibodies, one can search
for idiotope target region in the respective idiotypic immuno-
globulins.
We have used this method (3) and searched for inverse
hydropathies in human anti-HIV-1 antibodies for regions
which are recognized by a murine monoclonal antiidiotypic
antibody which reacts with a shared AIDS disease-specific idi-
otope (5, 6). This antibody, called 1F7, "sees" an idiotope
expressed by human antibodies against HIV-1-encoded pro-
teins and is only detected in individuals infected with HIV-1.
For this study, the VH and VL cDNAs of 1F7 were cloned and
sequenced. The sequence region predicted by inverse hydropa-
thy for interaction with the variable regions of 1F7 are in the
FR3-CDR3 regions of heavy chains of lF7-positive human anti-
HIV antibodies (7). Here we show that in sera of infected
individuals antibodies exist which bind to a peptide derived
from the heavy FR3/CDR3 region of human anti-HIV-1 anti-
bodies predicted as idiotypic target for the 1F7 antiidiotype
mAb.
Methods
Sequence determination of the exon for IF7 VHand VL Total RNAwas
isolated from 1 x 107 1F7 hybridoma cells by the procedure described
by Chomczynski and Sacchi (8). mRNAwas prepared by passage
through two cycles of chromatography on oligothymidylate-cellulose
columns (9). First strand cDNA was synthesized using SuperScript
Preamplification kit (GIBCO/BRL, Gaithersburg, MD). The DNAfrag-
ment encoding the VH of 1F7 was then amplified by PCRusing the 5'-
primer GGGAATFCATGRAATGSASCTGGGTYWTYCTCTfand
the 3 '-primer CCCAAGCTTCCAGGGRCCARKGGATARACIGR-
TGG(I = inosine, R = A or G, Y = C or T, K = G or T, S = C or
G, W= A or T) corresponding to sequences of the leader (signal
peptide) region, amino acids from -20 to -13, and the it constant
region, amino acids 126-119. In addition, the 5'-primer contains the
EcoRI site and the 3 '-primer contains a HindIll site, providing an alter-
native cloning strategy (Novagen, Inc., Madison, WI). To minimize the
error rates in PCR amplification, pfu DNApolymerase (Stratagene,
Inc., San Diego, CA) was used for amplification. Mutant frequency with
this thermostable DNApolymerase is '/1o compared with Taq DNA
polymerase. The fragment of cDNA amplified was subcloned into pT7
plasmid and NovaBlue competent cells were transformed using a proto-
col provided by the supplier (Novagen Inc.). Plasmid DNAwas pre-
pared by miniprep procedure (9) and the DNAsequence of the double-
stranded plasmid was determined by Sequenase Version 2.0 kit (U.S.B.
Biologicals, Cleveland, OH). The sequence of the DNA insert in the
plasmid was determined from both orientations using T7 promoter
primer (TAATACGACTCACTATAGGG)and U-19 primer (GTT-
Idiotype-specific Autoantibodies in AIDS 775
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/95/08/0775/06 $2.00






























Figure 1. Translated amino acid sequence of VL (a) and VH(b). IdB5.7
VH is aligned with 1F7 VHand M-T30 Vk with 1F7 Vk showing highest
homologies with 1F7 chains. Underlined residues indicate amino acid
differences.
TTCCCAGTCACGACGT).At least three clones were picked for se-
quence determination. The sequence of the 1F7 light chain was similarly
determined.
Peptides. Peptide 422(LRSVDTAIYYCARL), 436(QLTSVK-
AVDTAIYYCARL), and control peptide 291 (CYSKNQRNESSH-
GGE) were synthesized on a 431A Peptide Synthesizer (ABI Advanced
Riotechnologies, Inc., Columbia, MD) utilizing FMOCchemistry. p436
contains NH2-terminal additional sequence derived from 71-31 mAb;
p291 is derived from the calmodulin-binding domain of rat plasma
membrane Ca2' ATPase isoform 3.
Peptide-binding ELISA. Plates were coated with 100-il peptides at
concentration of 10 ag/ml, overnight at 4°C. After blocking at room
temperature for 1 h, 1F7 at 0, 20, 40, 60, 80, and 100 ,ug/ml or 0, 0.01,
0.1, 1, and 10 jig/ml were added and incubated at 37°C for 2 h. After
washing, peroxidase-labeled goat anti-mouse IgM-horseradish peroxi-
dase (HRP) (1:1,000 dilution) (Southern Biotechnology Associates,
Birmingham, AL) was used and left at room temperature for 1.5 h. After
washing as above, enzyme activity was revealed by o-phenylendiamine
dihydrochloride substrate (Sigma Chemical Co., St. Louis, MO)reading
at 490 nm. Alternatively, human sera, 1:1,000 diluted, were added to
peptide-coated plates. After washing 1:1,000 diluted goat anti-human
IgG-HRP was added and ELISA was developed as above.
Id inhibition assay. To determine the idiotype specificity of rabbit
anti-p422 sera, rabbit anti-p422 sera was added to p422-coated plates
together with 1F7 (IgM, K) or TEPC 183 (IgM, K) at different concen-
trations at 37°C for 2 h. ELISA was developed with goat anti-rabbit
HRP. Similarly, HIV+ sera, 1:800 diluted, was added together with
1F7 or TEPC 183 to p422-coated plates and ELISA was developed
with goat anti-human Ig HPR (1:1,000 diluted). Inhibition rate was
calculated using the equation:
%inhibition = 100 x (1 Absorbance with inhibitor (1)
Absorbance without inhibitor
Biotinylation of p422 and IF7-binding assays. NHS-LC-Biotin was
linked to p422 utilizing a commercial kit (Pierce Chemical Co., Rock-
ford, IL). To measure the binding ability of biotinylated-p422 to 1F7,
plates were coated with 1F7 at 2 Ag/ml overnight at 4°C. Free sites
were blocked at room temperature for 1 h. Biotinylated-p422 was added
and incubated at 37°C for 2 h. Bound p422 was visualized by streptavi-
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Figure 2. Schematic representation of predicted interaction between
CDRsand FRs of the 1F7 antiidiotype antibody and VHregions of three
human anti-HIV-l antibodies. The open boxes are CDRs from VL and
VH of 1F7, the closed boxes are CDRsfrom the VH of 257-D, 268-D,
and 71-31. Arrows indicate complementary contacts. Regions with dou-
ble lines and letters indicate IDR (14).
Rabbit anti-p422 antibodies. Rabbits were immunized with keyhole
limpet hemocyanin-conjugated peptide, 100 jig in CFAand IFA. After
the 4th immunization the sera were tested. Rabbit serum was added to
p422-coated plates and binding was detected by goat anti-IgG HRP
(Southern Biotechnology Associates). Inhibition of rabbit sera binding
by human HIV+ sera was done by coincubation with rabbit anti-p422
sera. Inhibition of binding was calculated as described above.
Humansera. Serum samples from 30 asymptomatic HIV-1 -infected
individuals were purchased from North American Biologicals Inc., (Mi-
ami, FL). Serum samples from 25 HIV-1-infected individuals with
confirmed clinical status of AIDS were obtained from Dr. Michael
McGrath, UCSF, San Francisco, California. Plasma specimens and se-
rum of babies perinatally infected with HIV-1 of PI and P2 status were
obtained from Dr. Savita Pahwa, North Shore University Hospital, Man-
hasset, New York, and Dr. P. A. Tovo, University of Turino, Turino,
Italy.
Results
Cloning and DNAsequencing of VHand VL of IF7 antiidiotype
antibody. The genes coding for the variable heavy and light
chain domains of the 1F7 antibody were cloned using VH and
VL-specific primers. The nucleic acid sequence of the cDNA
clones were determined using standard methods (see Methods).
The translated sequence of the variable regions of heavy and
light chain are shown in Fig. 1, a and b. Computer homology
search of the Kabat data bank (10) indicated homologies for
the heavy chain of 1F7 with an anti-Id antibody against a (1-
6) Dextran antibody ( 11 ) and for the light chain with an anti-
CD4 antibody M-T380 (12).
Identification of idiotypic contact regions for IF7 and de-
sign of idiotope target peptide for 1F7. Regions of inverted
hydropathy were searched for between the 1F7 antiidiotypic
antibody and several human anti-HIV-1 antibodies to identify
potential contact sites between the 1F7 and anti-HIV-1 antibod-
ies (3). The hydropathic profiles of the 1F7 VL and VH were
compared to the hydropathic profiles of the anti-gpl2O (MN)
mAbs, 268-D and 257-D, the anti-p24 mAb71-31 and the anti-
gp4l mAb98-6 (7). Previously, we have found that these three








Figure 3. Design of 1F7
idiotope peptide. The
CDRand FR regions of
three 1F7-positive anti-
bodies are shown. The
underlined sequences
were used to design the
p422 peptide.
human mAbs, 268-D, 257-D, and 71-31 bind to 1F7, i.e., are
1F7 Id positive (6). The hydropathic profile of a running win-
dow of at least six amino acids from 1F7 were scanned against
the human anti-HIV-1 antibody sequences. 1F7 was also
scanned against itself as control. The sequences were scanned
in both directions. The indicated potential contact sites between
1F7 and its 1F7 Id-positive anti-HIV-1 antibodies are indi-
cated schematically in Fig. 2.
Five regions from 1F7 match with five regions of the Id
antibodies, most of which are at or near CDRs (Fig. 2). One
hit occurs with 257-D, which overlaps with one of the hits from
268-D, and two hits occur with 71-31, both of which are in the
framework 3 (FR3) of 71-31. The three mAbs, which are 1F7
positive, display hits with the CDRregions of 1F7. In contrast,
the 1F7 negative 98-6 mAbindicates complementary sites only
in the in FR regions. Interestingly, 1F7 when scanned against
itself, reveals a hit at FR2-L2 and H2. Since these two chains
of 1F7 must associate to form a functional immunoglobulin
molecule, it is not unexpected that some complementarity is
displayed. The regions of complementarity that are presented
on the surface of the Ig molecule, such as those at or near the
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ies, i.e., antiidiotypic antibodies. Such sites have been pre-
viously described by us in generic terms as idiotope determining
regions (IDR) on the basis of surface variability plots (13, 14).
A complementary idiotype target peptide for the 1F7 was
designed based on the IDRs of 257-D, 268-D, and 71-32 con-
sisting of 14 amino acids. The peptide and its parental origin
are shown in Fig. 3. This peptide is called p422.
Binding of 1F7 to idiotope target peptide p422. To demon-
strate that the 14 mer p422 peptide is the target for the antiidio-
typic 1F7 mAbwe tested the binding of 1F7 to p422. ELISA
plates were coated with different amounts of p422 peptide or
control peptides, p291 and p436. After washing, coated plates
were incubated with 1F7 at different concentrations and bound
1F7 (IgM, K) was detected with peroxidase-labeled goat anti-
mouse IgM. As seen in Fig. 4 a, 1F7 bound to p422-coated
plates in concentration-dependent fashion and did not bind to
the control peptide p291, or to p436 (Fig. 4, b and c. An
unrelated mouse IgM, TEPC183, was used as control in binding
to p422-coated plates (Fig. 4 d).
The p422-1F7 interaction was also demonstrated by re-
versing the ELISA configuration. Plates were coated with 1F7
and incubated with dilutions of biotin-conjugated p422 peptide.
As seen in Fig. 5 a, increasing concentrations of biotinylated
p422 peptide added to IF7-coated plates produced increasing
ELISA reading with enzyme-labeled avidin. Next, the specific-
ity of p422 binding to 1F7 was tested by inhibition experiments.
As shown in Fig. 5 b, the binding of 1F7 to 1F7 Id-positive
antibodies in HIV-positive serum is inhibited dose dependently
by p422 but not by the control peptide p291.
Collectively these data demonstrate that the 1F7 antiidiotype
mAbbinds to a peptide derived from the sequences of human
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Figure 4. (a) Binding of 1F7 to
p422-coated plates. Plates were
d coated with increasing amounts of
p422 peptides and different con-
centrations of 1F7 were added.
After washing ELISA was devel-
oped with goat enzyme-labeled
anti-mouse IgM. (b and c) Bind-
ing of 1F7 to control peptides
p291 and p436 using identical
ELISA. (d) Binding of TEPC 18310o to p422-coated plates. ELISA as
in a.
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Figure 5. (a) Binding of
p422-biotin conjugate to
1F7. Plates were coated
with increasing amounts
of IF7; biotin-conju-
gated p422 peptide was
added in different
amounts and ELISA was
developed using en-
zyme-conjugated avid-
ine. (b) Inhibition of 1F7
binding to anti-HIV-l
antibodies by p422 and
control p291. Plates were
coated with goat anti-
IgM; IF7-positive hu-
man serum was coincu-
bated with different
amounts of p422 or p291
peptide. ELISA was de-
veloped with goat anti-
IgG-HRP.
utility of the inverse hydropathy relationship in protein-protein
interaction as a method to search for sequences involved in
protein binding.
To further confirm that the p422 peptide expresses the idio-
tope target for the 1F7 antiidiotype mAb, a polyclonal antibody
against p422 was produced in rabbits. Rabbit anti-p422 serum
binds to p422 coated plates (Fig. 6 a), but does not bind to
control peptide p291-coated plates. If p422 is the 1F7 idiotope
or a major part of this idiotope, the binding of rabbit anti-p422 to
p422 should be inhibited by 1F7. As seen in Fig. 6 b, increasing
amounts of 1F7 produced strong inhibition of p422 binding,
while the unrelated mouse IgM TEPC 183 did not inhibit bind-
ing. These results demonstrate that the p422 peptide contains
antigenic structures recognized by both the mouse monoclonal
and the rabbit polyclonal antibody thereby confirming the idio-
topic antigenicity of the p422 sequence.
Binding of serum antibodies from HPV-I -infected individu-
als to the 1F7 idiotopic peptide p422. 1F7 binds to a shared
idiotope on anti-HIV-1 antibodies with different specificities
(5,6) and is only found in HIV-1 -infected individuals. Because
of this broad reactivity and association with HIV infection, it
is conceivable that the 1F7 idiotope is also the target for self-
recognition in infected individuals; in other words, autoantibod-
ies might exist in seropositive individuals which recognize the
1F7 idiotope.
Sera from 51 HIV-1-infected individuals were tested for
binding to p422-coated plates in ELISA. Fig. 7 a shows a repre-
sentative ELISA with one HIV+ serum in which anti-p422
activity is detectable. The binding is dilution dependent for both
p422 and serum. A pool of sera from uninfected individuals
shows no binding to p422 (Fig. 7 b). No binding is detected
with the HIV+ serum to the control peptide (Fig. 7 c). The
specificity of binding to p422 was tested by using the 1F7
antibody as competitor for HIV+ serum. As seen in Fig. 7 d,
1F7, but not the control IgM TEPC 183, competes with HIV+
serum for binding to p422 peptide.
Finally, the possibility that the binding of serum antibodies
to 1F7 may be nonspecific and unrelated to the p422 idiotypic




















Figure 6. (a) Binding of rabbit anti-p422 serum to p422-coated plates.
p422-coated plates were incubated with dilutions of rabbit antisera and
ELISA was developed using enzyme-labeled goat anti-rabbit IgG. Sera
were also added to p291-coated plates as control. (b) Inhibition of
binding of rabbit anti-p422 sera to p422 by 1F7 and TEPC183. Dilutions
of rabbit sera were coincubated with different amounts of 1F7 or TEPC
183 and added to p422-coated plates.
can be inhibited by p422 and that the background binding to
a control murine IgM, TEPC 183, is not affected by p422
(Fig. 8).
Since not all HIV-l -infected individuals produce 1F7 reac-
tive antibodies, (- 70% are 1F7 positive [5, 6]), it was of
interest to ask whether the expression of 1F7 Id and autoanti-
Id are associated or not. Serum samples from IF7-positive and
IF7-negative individuals were assayed for binding to p422 pep-
tide. As seen in Table I, 31 out of 51 1F7+ sera also contained
anti-p422 antibodies; none of 4 1F7 Id-negative HIV seroposi-
tive sera react with p422. No binding to p422 was seen in non-
HIV-1 infected IF7-Id-negative seroreverting babies (Table I)
and in seronegative sera from 20 adult HIV-seronegative blood
donors (data not shown). We also tested sera from infected
babies and found that 22/27 IF7-positive sera contained anti-
bodies to p422 (Table I).
These results show that the autoantiidiotypic, i.e., IF7-like,
activity is correlated with the expression of the corresponding
1F7 idiotype.
Discussion
In this report we describe a peptide which is recognized by
antibodies in sera from HIV-1-infected individuals. This pep-
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Figure 7. (a) Binding of human
HIV-1 + serum to p422. Serial di-
lutions of serum from an HIV- 1-
infected individual were added to
d p422-coated plates. Binding anti-
bodies were detected using en-
zyme-labeled goat anti-human
IgG. (b) Absence of binding of
normal human serum to p422. (c)
Absence of binding of human
HIV-1 + serum to p291. (d) Inhi-
bition of binding of human HIV-
1+ serum to p422 by 1F7 and
TEPC 183. Human HIV-1+ se-
rum (1:800 diluted) was added in
presence of increasing amounts of
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Figure 8. Inhibition of HIV+ serum antibody binding to 1F7 or TEPC
183 by p422. Plates were coated with goat anti-IgM, 1F7 (IgM, K), or
TEPC 183 (IgM, K) were added together with increasing amount of
p422; IF7+ serum was added and ELISA was developed with goat
anti-human IgG-HRP.
tide was designed from the sequence of human monoclonal
antibodies against the viral envelope proteins gpl20 and gp4l,
which react with a monoclonal antiidiotypic antibody recogniz-
ing a shared idiotope in sera of HIV-1-infected individuals
(6). A search for inverse hydropathies (3, 4) between the mono-
clonal antiidiotypic antibody and human antienvelope antibod-
ies indicated potential idiotope contacts which provided the
sequence information for the peptide design. The sequence re-
gion used for the synthesis of the peptide comes from the FR3/
CDR3regions of heavy chains of the human anti-HIV-1 anti-
bodies.
The molecular recognition theory (4) has been used pre-
viously to generate antiidiotypic antibodies against autoantibod-
ies and antibodies against hormones and receptors (for review
see reference 3). This approach was used here to identify con-
tacts between monoclonal idiotype and antiidiotype antibodies.
This system is of considerable interest since the shared 1F7
idiotype is involved in cytotoxic effector function (Grant, M.,
M. Gomez, and F. Smail, unpublished data) and as target for
enhancing apoptosis of T cells from infected individuals
(Muller, S., P. Brams, and H. Collins, unpublished data). The
hydropathy analysis predicted the CDRregions which are in-
volved in contacts between 1F7 and the human anti-HIV-1
antibodies. While the idiotope target region for 1F7 could be
mimicked by a peptide, peptides synthesized from 1F7 (anti-
Id) CDRs failed to bind to anti-HIV-1 antibodies (data not
shown). This suggests that the binding site of the 1F7 anti-
Id is composed of more than one CDRarranged in a three-
dimensional configuration, a model, compatible with our current
Table L
No. of No. of anti-p422 Percent Id+
Sera 1F7 Id+ (anti-Id) and anti-Id+
HIV-1+ adult* 51 31 62
HIV-1 + babiest 27 22 81.5
* None of 4 HIV-1 + 1F7 Id negative sera was anti-P422 (anti-Id
positive). * None of 25 1F7 negative, sero-reverting baby sera was anti-
P422 (anti-Id) positive.




















understanding of antibody structure. In contrast, the idiotope
target (idiotype seen by 1F7) appears to consist predominantly
of a linear region which covers sequences from the framework
and CDR. The combined involvement of framework together
with hypervariable regions has been predicted by our previously
described IDR model (14).
In the strictest sense these antipeptide antibodies are not
autoantibodies since the peptides used were not derived from
anti-HIV in sera studied here. However, because 1F7 binds to
monoclonal human anti-HIV antibodies (6), which provided
the sequence data for designing the p422 peptide, the human
antipeptide antibodies are homologous autoantibodies. There-
fore, we are using the term autoantibodies in this report.
The autoantibodies against a self IDR described here in
sera from HIV-infected individuals are the second example of
autoantibodies against a linear, peptide-defined, variable immu-
noglobulin epitope. Previously (15) we have identified another
IDR consisting of CDR2-FR3 VHsequences recognized by anti-
bodies in sera of certain mouse strains and of humans. This
IDR is part of the murine germ line gene S107 Vl. In mice
antibodies against phosphorylcholine, the dominant epitope of
C-polysaccharide, utilize the VI germ line gene. While autoanti-
bodies against CDR2-FR3 of S 107 VI recognize a nonmutated
IDR, the antibodies against the p422 IDR peptide, described
here, react with an IDR generated in part by somatic mutational
and selective events. This is not unexpected since the infection
with HIV- 1 in evolution is a recent event not allowing for
coselection of germ line-encoded IDRs. The 1F7 IDR de-
scribed by the p422 peptide, is quite unique as it is not present
on the 1F7 Id-negative human monoclonal anti-HIV-1 anti-
body 98-6 (6) and because a computer search of the sequence
data bank ( 10) did not identify other antibodies with an identical
sequence in this VH location except the IDR expressing 71-31
VH (7). The generation of the p422 IDR by somatic and selec-
tive processes is further supported by the finding that this IDR
is found on antibodies belonging to different VH gene families
(16). On the other hand, the sequence of the 1F7 antiidiotypic
antibody has high homologies in both chains with two other
antibodies directed against members of the Ig superfamily, an
anti-Id (11) and an anti-CD4 (12), respectively, see Fig. 1.
The reasons why the humoral immune response to HIV
antigens selects for antibodies expressing the 1F7 IDR are un-
clear, but the participation of this epitope as described in several
HIV infection-related immunological systems (6, 16; Grant,
M., M. Gomez, and F. Smail, unpublished data; Miller, S., P.
Brams, and H. Collins, unpublished data) suggests a biological
activity of the 1F7 like autoantibodies in sera of infected indi-
viduals.
The murine 1F7 monoclonal antiidiotypic antibody reacts
with anti-HIV-1 antibodies of different specificities (5, 6). 1F7
Id has been detected in all stages of HIV-1 infection (5; Grant,
M., M. Gomez, and F. Smail, unpublished data), as well as in
serum from gpl20/160 vaccine volunteers and also in sera of
experimentally HIV-1-IIIB-infected chimpanzees (17). 1F7
has also been shown to play a role in cytotoxic T lymphocyte
activity as it suppresses cytotoxicity in vitro (Grant, M., M.
Gomez, and F. Smail, unpublished data).
Collectively, the data on 1F7 reactivity with antibodies and
T cells in HIV-l -infected individuals shows that this idiotype
is involved in the immune response to HIV-1 infection. The
finding of an autoantiidiotypic humoral response against the
1F7 idiotype, reported here, adds further evidence for a biologi-
cal role of 1F7 in AIDS. The significance of identifying the
molecular target for 1F7 as a CDR-FR peptide lies in the
potential to manipulate the immune response to HIV infection
using peptide-based vaccines. What exactly the role of 1F7-like
antibodies is remains subject to speculation at this time, and
this question requires further studies.
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